Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

Todd Neale

September 01, 2022

News Conference News ESC 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Yael L. Maxwell

August 31, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

Presentation ESC 2022

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Presenter: Michelle L. O’Donoghue

August 29, 2022

Presentation ESC 2022

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Presenter: John Eikelboom

August 29, 2022

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Todd Neale

August 28, 2022

News Conference News ESC 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

Shelley Wood

August 27, 2022

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

News Conference News ESC 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection

Todd Neale

August 26, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

Advertisement

CV Care Around Noncardiac Surgery: New ESC Guidelines

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

Polypill Bests Usual Care in Patients With Recent MI: SECURE

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection

What’s Going to Be Hot at ESC 2022?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content